FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDRH | April 19, 2004 | 9 a.m. - 6 p.m. | Holiday Inn |
Agenda:
The committee will discuss the following issues:
(1) Mechanisms to reduce the regulatory and inspection burden on facilities;
(2) Whether mammographic images obtained from reconstructed compressed digital
data (lossless or lossy data compression) can be used for primary interpretation
or storage;
(3) Whether images obtained from digitized film-screen mammograms can be used
for primary interpretation or storage; and
(4) Revisions to Mammography Quality Standards Act (MQSA) compliance guidance.
The committee will also receive updates on recently approved alternative standards,
full field digital mammography accreditation and certification, the inspection
demonstration program, the status of MQSA reauthorization, and the new post
inspection enforcement strategy.
The MQSA compliance guidance documents, which are in a question and answer format,
are available to the public on the Internet at http://www.fda.gov/cdrh/mammography.
This guidance is updated continually in response to questions that FDA receives
from the public.
Background material and meeting information
will become available no later than the day before the meeting (Simply select
the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by April 5, 2004. Oral presentations from the public will be
scheduled between approximately 9:30 a.m. and 10:30 a.m. on April 19, 2004.
Time allotted for each presentation may be limited. Those desiring to make formal
oral presentations should notify the contact person before April 5, 2004, and
submit a brief statement of the general nature of the evidence or arguments
they wish to present, the names and addresses of proposed participants, and
an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency
is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Shirley Meeks, Conference Management Staff, at 301-594-1283,
ext. 105, at least 7 days in advance of the meeting.
Contact Person:
Charles Finder, Center for Devices and Radiological Health (HFZ-240), Food and
Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3332, or
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 3014512397. Please call the Information Line for
up-to-date information on this meeting.
[ Full FR Notice ]